# US RNA-Based Therapeutics Market

> US RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.7%
- **2024:** $ 2,764.28 Million
- **2025:** $ 2,921.84 Million
- **2035:** $ 5,085.43 Million
- **Key Players:** Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US), Silence Therapeutics (GB), Sarepta Therapeutics (US)

**Report ID:** MRFR/Pharma/51011-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-rna-based-therapeutics-market-52771

---

## Market Summary

## **US RNA-Based Therapeutics Market Overview**

As per MRFR analysis, the US RNA-Based Therapeutics Market Size was estimated at 1.62 (USD Billion) in 2023. The US RNA-Based Therapeutics Market Industry is expected to grow from 2 (USD Billion) in 2024 to 6.5 (USD Billion) by 2035. The US RNA-Based Therapeutics Market CAGR (growth rate) is expected to be around 11.31% during the forecast period (2025 - 2035).

### **Key US RNA-Based Therapeutics Market Trends Highlighted**

The US RNA-Based Therapeutics Market is experiencing significant growth, driven by the increasing incidence of genetic disorders and the rising demand for more effective treatment options. One of the key drivers in this market is the advancement in RNA technology, particularly in messenger RNA (mRNA) therapeutics, which has gained immense popularity following the success of mRNA vaccines during the COVID-19 pandemic.

This technological evolution not only provides new avenues for personalized medicine but also enhances the development of targeted therapies for various diseases. Additionally, federal support through initiatives and funding from public health agencies is bolstering research and development activities in this sector, contributing to its rapid expansion.

There are considerable opportunities to be explored in the US RNA-Based Therapeutics Market, especially in the fields of cancer treatment and rare diseases. The ongoing research into RNA interference (RNAi) and antisense oligonucleotides presents promising avenues for innovation. Furthermore, collaborations between biotech firms and research institutions are likely to yield new therapeutics and delivery methods.

The evolving regulatory landscape in the US, along with accelerated approval pathways for RNA-based therapies, represents another opportunity that can be effectively captured by stakeholders in the market. Recently, the trend has shifted towards increasing investments in RNA-based platforms, as more companies seek to develop RNA therapeutics beyond vaccines.

Several pharmaceutical companies are now investing in manufacturing processes that enhance the scalability and efficiency of nucleotide production. The rise of patient-centric approaches and the focus on precision medicine further emphasize the need for continued innovation in RNA therapeutics. As the US market continues to adapt and grow, ongoing advancements are expected to mark a transformative period for RNA-based treatments, promoting better health outcomes across various patient populations.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **US RNA-Based Therapeutics Market Drivers**

### **Rising Prevalence of Genetic Disorders**

The increasing prevalence of genetic disorders in the United States is a significant driver for growth in the US RNA-Based Therapeutics Market Industry. According to the National Institutes of Health (NIH), genetic disorders affect millions of Americans, with over 6,000 recognized disorders that can be attributed to genetic causes. This prevalent genetic landscape necessitates innovative treatments such as RNA-based therapies, which have shown promise in addressing these disorders at their root cause.

Leading organizations, including the American Society of Human Genetics, emphasize the need for more targeted therapies due to the escalating number of diagnosed genetic conditions, thereby fostering an environment conducive to advancements in the RNA-based therapeutics sector.

### **Advancements in Research and Development**

The US RNA-Based Therapeutics Market Industry is poised for substantial growth owing to significant advancements in Research and Development (R&D) activities. The US government has prioritized funding for biotechnology, resulting in increased investments in RNA-related research. The National Science Foundation reported a consistent increase in funding for biomedical and biotechnology research, amounting to over USD 38 billion in recent fiscal years.

These investments fuel innovations in RNA-based therapeutics, enabling researchers and companies to develop more effective treatments. Established organizations such as Moderna and BioNTech have successfully utilized RNA technology to create vaccines, further validating the potential applications of RNA therapeutics in various diseases.

### **Increased Recognition of RNA Therapies**

The growing recognition and acceptance of RNA therapies among healthcare professionals and stakeholders are driving the US RNA-Based Therapeutics Market Industry forward. Regulatory bodies, including the Food and Drug Administration (FDA), have accelerated the approval process for RNA-based treatments, recognizing their potential in addressing previously untreatable diseases. Recently, the FDA granted Breakthrough Therapy Designation to several RNA therapeutics aimed at rare diseases, underscoring the urgency in developing these drugs.

As a result, more pharmaceutical companies are pursuing RNA-based solutions, leading to a broader pipeline of therapies and a notable increase in market activity.

### **Collaborative Efforts Among Biotech Firms**

The US RNA-Based Therapeutics Market Industry is significantly improved by the collaborations among biotechnology firms. The trend of partnerships for the co-development of RNA technologies has become more prevalent as companies endeavor to combine their resources and expertise. For example, the partnership between BioNTech and Pfizer underscores the potential of such partnerships to accelerate the development of RNA-based therapeutics.

These alliances are essential for navigating the intricate landscape of RNA therapeutics, as they provide access to shared technology, funding, and research capabilities. According to the Biotechnology Innovation Organization, such collaborations are predicted to continue growing, further driving innovation and market expansion in the US.

## **US RNA-Based Therapeutics Market Segment Insights**

### **RNA-Based Therapeutics Market Technology Insights**

The Technology segment of the US RNA-Based Therapeutics Market is characterized by significant advancements and a diverse array of applications that demonstrate the potential of RNA technologies in treating various diseases. RNA Interference has emerged as a dominant force in the market, allowing for targeted gene silencing, which is crucial in addressing genetic disorders and reducing the prevalence of certain diseases.

The ability to specifically inhibit gene expression not only has therapeutic implications but also provides a powerful tool in Research and Development studies for understanding gene functions. Antisense Oligonucleotides have garnered attention for their efficacy in modulating gene expression and are often used in the treatment of neurological conditions and rare genetic disorders.

The ability to design these oligonucleotides to target the specific RNA sequence makes them an invaluable asset in tailoring personalized medicine approaches. mRNA Therapeutics have revolutionized treatment paradigms, especially highlighted during the recent pandemic with mRNA vaccines showcasing their rapid development capabilities. These technologies enable the delivery of genetic information into cells efficiently, generating an immune response or producing therapeutic proteins necessary for disease management.

Furthermore, CRISPR Technology has redefined gene editing by providing precise and versatile tools for modifying genomes, which is essential for treating genetic disorders and advancing therapies in various fields such as oncology and agriculture. As the market evolves, these technologies drive innovation, presenting new opportunities while also facing challenges related to regulatory frameworks and ethical considerations.

The growth of these segments within the US RNA-Based Therapeutics Market illustrates the dynamic interplay of scientific progress and clinical application, underscoring the transformative potential of RNA-based solutions in healthcare.

$IMAGE2_HERE$

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **RNA-Based Therapeutics Market Application Insights**

The US RNA-Based Therapeutics Market is rapidly evolving, with significant advancements in various applications including Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. The demand for RNA-based treatments in Oncology is particularly strong due to the rising prevalence of cancer, driving research towards targeted therapies that improve patient outcomes. Infectious Diseases have also seen a surge in interest, especially highlighted by the recent global health crises, prompting the development of RNA therapies for efficient vaccine design and rapid responses.

Genetic Disorders represent another critical area, as RNA technology holds promise for addressing previously untreatable conditions by targeting gene expression and providing innovative solutions. Cardiovascular Diseases, among the leading causes of mortality in the US, benefit from RNA-based approaches aimed at gene regulation and potential interventions. Each of these applications showcases a significant opportunity within the US RNA-Based Therapeutics Market, underpinned by ongoing research and development initiatives aimed at harnessing RNA technology to treat complex health challenges effectively.

As the market progresses, these applications are likely to play a pivotal role in shaping the future of therapeutic interventions in the healthcare landscape.

### **RNA-Based Therapeutics Market End Use Insights**

The US RNA-Based Therapeutics Market is seeing a considerable shift within its End Use segment, primarily influenced by the demand from Pharmaceutical Companies, Research Institutions, and Contract Research Organizations. Pharmaceutical Companies play a significant role in the development and commercialization of RNA-based therapies, often focusing on innovative treatment solutions that address critical medical needs. Research Institutions are crucial for advancing RNA technology and conducting essential studies that contribute to knowledge creation in this dynamic field.

These institutions often collaborate with pharmaceutical firms, facilitating the translation of research into practical applications. Contract Research Organizations provide essential services that support both pharmaceutical companies and research institutions, enabling efficiency in clinical trials and regulatory processes. Their prominence in this market stems from the increasing complexity of drug development, requiring specialized expertise and resources. As the US government continues to invest in healthcare innovation, the entire RNA-based therapeutics ecosystem is poised for growth, fueled by advances in genetic research and personalized medicine.

This segment's contributions are vital for driving market trends and enhancing patient outcomes across various therapeutic areas.

### **RNA-Based Therapeutics Market Delivery Method Insights**

The Delivery Method segment of the US RNA-Based Therapeutics Market is crucial for the effective transport of therapeutic agents to target cells. Various techniques are utilized within this segment, including Liposomes, Nanoparticles, Viral Vectors, and Electroporation, each with its unique advantages. Liposomes often increase the stability and bioavailability of RNA-based drugs, enhancing their therapeutic efficacy. Nanoparticles are valued for their ability to facilitate cellular uptake and enable targeted delivery, overcoming barriers often faced by traditional delivery methods.

Viral Vectors leverage the natural ability of viruses to deliver genetic material into cells, making them a powerful tool for gene therapy. Electroporation employs electric fields to enhance cell permeability, allowing for more efficient delivery of RNA molecules. The growth in this segment is supported by increasing investments in innovative drug delivery technologies and advances in Research and Development. Continued focus on improving delivery efficiency and patient outcomes indicates promising opportunities within the US RNA-Based Therapeutics Market, further emphasizing the significance of the Delivery Method segment in shaping future therapeutic landscapes.

## **US RNA-Based Therapeutics Market Key Players and Competitive Insights**

The US RNA-Based Therapeutics Market has experienced a surge in innovation and competition, reflecting the growing significance of RNA technologies in drug development. This market encompasses a range of therapeutic modalities that utilize RNA as a central component in targeting diseases, particularly genetic disorders, cancers, and infectious diseases. Increasing investments from both public and private sectors, advancements in delivery mechanisms, and a favorable regulatory environment have contributed to the rapid growth of this market.

Companies operating within this space have been focusing on developing novel therapeutics that leverage messenger RNA (mRNA), small interfering RNA (siRNA), and other RNA-based platforms to address unmet medical needs. As the landscape evolves, understanding the competitive dynamics among key players will be essential for stakeholders looking to navigate this promising market.

CureVac has positioned itself as a notable player in the US RNA-Based Therapeutics Market, particularly with its focus on mRNA technology to develop innovative vaccines and therapeutics. The company’s strength lies in its proprietary mRNA technology platform, which is designed to enable the creation of a diverse range of treatments, including those for oncology and infectious diseases. CureVac has established a strong presence in the US through strategic collaborations with various biopharmaceutical firms and research institutions, allowing it to leverage additional expertise and resources.

The company’s focus on achieving high efficacy and safety profiles in its RNA-based therapeutics has garnered attention from both investors and healthcare professionals, contributing to its continued growth and innovation in this competitive arena. BioNTech has emerged as a leading force in the US RNA-Based Therapeutics Market, particularly noted for its breakthrough mRNA therapies and vaccines. The company gained significant recognition with its rapid development of an mRNA-based COVID-19 vaccine, showcasing the potential of RNA technologies in responding to urgent public health challenges.

BioNTech's strength lies not only in its cutting-edge scientific capabilities but also in its established partnerships with major pharmaceutical companies, enhancing its development and commercialization efforts in the US market. The company continues to expand its pipeline, targeting various therapeutic areas such as oncology and autoimmune diseases, providing a robust array of products that cater to diverse patient populations. BioNTech's strategic mergers and acquisitions have also enabled it to bolster its capabilities in RNA science, thereby reinforcing its competitive position in the US RNA-Based Therapeutics Market and ensuring a strong foothold as the landscape continues to evolve.

### **Key Companies in the US RNA-Based Therapeutics Market Include**

### **US RNA-Based Therapeutics Market Industry Developments**

The US RNA-Based Therapeutics Market has seen significant developments recently. Companies like Moderna and BioNTech continue to expand their mRNA technology beyond vaccines, focusing on treatments for a range of diseases, including cancer and rare genetic disorders. In November 2023, Alnylam Pharmaceuticals announced promising results from a Phase III trial for its RNA interference therapy, which has fueled investor interest and boosted its market valuation significantly.

In terms of mergers and acquisitions, in September 2023, Sanofi completed the acquisition of Translate Bio, enhancing its capabilities in mRNA technology for therapeutic applications. Additionally, in October 2023, Pfizer announced a partnership with BioNTech to develop combined RNA-based therapies that target infectious diseases, reflecting a growing trend towards collaboration in this sector. Government initiatives are also supporting the RNA therapeutics field, with recent funding allocated for Research and Development in genetic medicine.

Over the past few years, the US market's momentum has accelerated, fueled by an increased focus on personalized medicine and innovations in delivery systems for RNA-based drugs. With ongoing advancements and strategic collaborations, the outlook for the US RNA-Based Therapeutics Market remains robust.

## **RNA-Based Therapeutics Market Segmentation Insights**

### **RNA-Based Therapeutics Market Technology Outlook**

### **RNA-Based Therapeutics Market Application Outlook**

### **RNA-Based Therapeutics Market End Use Outlook**

### **RNA-Based Therapeutics Market Delivery Method Outlook**

## Market Drivers

### Growing Demand for Personalized Medicine

The increasing emphasis on personalized medicine is driving the RNA-based therapeutics market. Patients are increasingly seeking treatments tailored to their genetic profiles, which enhances the efficacy of therapies. This trend is supported by advancements in genomic sequencing technologies, allowing for more precise targeting of diseases at the molecular level. The rna based-therapeutics market is projected to reach approximately $10 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 15%. This growth is indicative of the rising acceptance of personalized approaches in treatment protocols, which are becoming integral to healthcare strategies in the US.

### Increasing Prevalence of Genetic Disorders

The rising incidence of genetic disorders is a key driver for the RNA-based therapeutics market. Conditions such as cystic fibrosis, muscular dystrophy, and various rare diseases are becoming more prevalent, necessitating innovative treatment solutions. The US healthcare system is witnessing a surge in demand for therapies that can address these genetic conditions at their root cause. The rna based-therapeutics market is expected to see substantial growth, with estimates suggesting a market size of $8 billion by 2025, as healthcare providers seek effective interventions for these challenging disorders.

### Supportive Government Initiatives and Funding

Government initiatives aimed at promoting biotechnology and pharmaceutical innovation are bolstering the RNA-based therapeutics market. Increased funding for research and development, along with favorable policies, are creating a conducive environment for the advancement of RNA therapies. The US government has allocated significant resources to support biotech research, with funding levels reaching approximately $3 billion annually. This financial backing is crucial for fostering innovation and accelerating the development of RNA-based treatments, thereby enhancing the overall growth trajectory of the market.

### Rising Awareness and Acceptance of RNA Therapies

Public awareness and acceptance of RNA therapies are on the rise, positively influencing the RNA-based therapeutics market. Educational campaigns and successful case studies are helping to demystify RNA-based treatments, leading to greater patient and physician engagement. As of 2025, surveys indicate that over 60% of healthcare professionals are more inclined to recommend RNA therapies, reflecting a shift in perception. This growing acceptance is likely to drive market expansion, as more patients seek out these innovative treatment options for various conditions.

### Technological Advancements in RNA Delivery Systems

Innovations in RNA delivery systems are significantly impacting the RNA-based therapeutics market. The development of novel delivery mechanisms, such as lipid nanoparticles and viral vectors, enhances the stability and efficacy of RNA therapies. These advancements facilitate targeted delivery to specific tissues, thereby improving therapeutic outcomes. As of 2025, the market for RNA delivery technologies is expected to grow at a CAGR of 12%, driven by the need for more effective and safer delivery methods. This evolution in technology is crucial for the successful implementation of RNA-based therapies in clinical settings.

## Future Outlook

The [RNA Based Therapeutics Market](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) is projected to grow at a 5.7% CAGR from 2025 to 2035, driven by advancements in gene editing, increased R&D investments, and rising demand for personalized medicine.

**New opportunities:**

- Development of RNA delivery systems for targeted therapies. Partnerships with biotech firms for innovative RNA-based solutions. Expansion into emerging markets with tailored RNA therapies.

By 2035, the RNA-based therapeutics market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Technology: mRNA Therapeutics (Largest) vs. CRISPR Technology (Fastest-Growing)

The US RNA-based therapeutics market is characterized by a significant distribution of market share among various technologies, with mRNA therapeutics leading due to their versatile applications in vaccine development and disease treatment. RNA interference and antisense oligonucleotides also hold considerable shares, but mRNA's dominance can be attributed to its success in recent therapeutic breakthroughs, particularly highlighted by COVID-19 vaccination efforts.

Growth trends in the US rna based-therapeutics market indicate a robust interest in CRISPR technology, recognized as the fastest-growing segment. This interest is driven by its potential for gene editing and therapeutic applications, which are reshaping treatment paradigms. Advancements in research and increasing investments into biotechnology enhance the feasibility and attractiveness of both CRISPR and mRNA technologies, stimulating a competitive landscape in the market.

Technology: mRNA Therapeutics (Dominant) vs. CRISPR Technology (Emerging)

mRNA therapeutics represent the dominant technology within the US rna based-therapeutics market, leveraging advancements in synthetic biology and having immediate therapeutic applications, especially in vaccines. Their established efficacy and innovative delivery systems enable them to address a wide array of health challenges. In contrast, CRISPR technology is viewed as an emerging sector, poised for rapid growth due to its transformative potential in genetic engineering. Its ability to offer precise modifications in genes places CRISPR in a competitive position, attracting significant research funding and interest from pharmaceutical companies aiming to harness its capabilities for novel therapeutic solutions.

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

In the US RNA-based therapeutics market, the application segment showcases prominent distribution among oncology, infectious diseases, genetic disorders, and cardiovascular diseases. Oncology holds the largest market share, driven by advancements in targeted therapies and increasing investments in cancer research. Infectious diseases, while currently smaller, are emerging swiftly due to rising global health challenges and the need for efficient treatment solutions.

Growth trends indicate that oncology will continue to dominate, fueled by the growing prevalence of cancer and novel therapeutic innovations. Conversely, the infectious diseases segment is recognized as the fastest-growing area, propelled by global outbreaks and investment in preventive measures against viral threats. This dynamic situation prompts a significant focus on both segments for future developments.

Oncology (Dominant) vs. Infectious Diseases (Emerging)

Oncology represents the dominant application in the US rna based-therapeutics market, characterized by a robust pipeline of innovative therapies that target various cancer types using RNA technology. This segment is marked by a high level of research activity, significant funding from both public and private sectors, and increasing partnerships between biotech companies and research institutions. On the other hand, infectious diseases are emerging with substantial momentum, driven by the need for rapid response solutions to outbreaks and pandemics. Innovative RNA-based therapies are being developed to address viral infections, further solidifying the importance of this segment. Both segments are crucial, with oncology leading in market strength while infectious diseases are quickly gaining ground.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

In the US RNA-based therapeutics market, the distribution of market share reveals that pharmaceutical companies occupy the largest segment due to their extensive resources and established distribution channels. With a significant investment in biopharmaceutical development and production capacity, pharmaceutical firms are well-positioned to dominate the market. Research institutions, while smaller in share, have shown rapid advancement owing to innovative research and collaborations with industry players.

Growth trends within this segment are primarily driven by increased investments in research and development among both pharmaceutical companies and research institutions. This trend is augmented by the rising prevalence of genetic disorders and the demand for precise treatment options. Contract research organizations also contribute to this growth by providing essential support services to facilitate the development of RNA-based therapeutics, enhancing the efficiency and effectiveness of the drug development process.

Pharmaceutical Companies (Dominant) vs. Research Institutions (Emerging)

Pharmaceutical companies represent the dominant force in the RNA-based therapeutics sector, leveraging their vast resources and capability for large-scale production. This segment benefits from significant investment in cutting-edge technologies and a robust infrastructure for drug development. On the other hand, research institutions serve as an emerging segment, characterized by agility and a strong focus on innovation. These institutions engage in groundbreaking research and often collaborate with pharmaceutical companies to bring novel therapies to market. The synergy between these entities fosters advancements in RNA-based therapies, which are crucial in addressing unmet medical needs and driving future growth in the market.

### By Delivery Method: Liposomes (Largest) vs. Nanoparticles (Fastest-Growing)

In the US RNA-based therapeutics market, the distribution of market share among delivery methods reveals that liposomes hold the largest portion due to their efficiency in encapsulating nucleic acid drugs and enhancing cellular uptake. This method has long been trusted for its safety profile and effective delivery, making it a preferred choice among researchers and biotechnology companies.

Conversely, nanoparticles are identified as the fastest-growing segment, driven by their versatility and ability to deliver RNA therapeutics across various biological barriers. The increasing demand for targeted therapies, along with advancements in nanoparticle technology, supports their rapid adoption. As more companies invest in nanoparticle formulations, this segment is expected to gain a significant market foothold in the coming years.

Liposomes (Dominant) vs. Nanoparticles (Emerging)

Liposomes are considered the dominant delivery method in the US rna based-therapeutics market due to their biocompatibility and ability to protect RNA from degradation, leading to enhanced therapeutic efficacy. They are widely utilized in various formulations, demonstrating excellent drug-loading capacity and minimal side effects. In contrast, nanoparticles represent an emerging delivery method that is gaining momentum due to innovations in their design and functionalization. Their ability to engage in targeted delivery, coupled with potential for personalized medicine solutions, positions them as a competitive alternative to traditional methods. As research progresses, both segments are set to play crucial roles in the future landscape of RNA-based therapies.

## Competitive Benchmarking

The RNA-based therapeutics market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in technology and increasing investment in research and development. Key players such as Moderna (US), Alnylam Pharmaceuticals (US), and Ionis Pharmaceuticals (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Moderna (US) continues to focus on innovation, particularly in mRNA technology, while Alnylam Pharmaceuticals (US) emphasizes its leadership in RNA interference (RNAi) therapeutics. Ionis Pharmaceuticals (US) is leveraging its proprietary antisense technology to expand its pipeline, indicating a collective shift towards specialized therapeutic solutions that cater to unmet medical needs.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. The market structure appears moderately fragmented, with several players vying for dominance. However, the influence of major companies is substantial, as they set the pace for innovation and regulatory compliance, thereby shaping the competitive environment.
In October Moderna (US) announced a strategic partnership with a leading biotechnology firm to develop next-generation mRNA vaccines targeting rare diseases. This collaboration is expected to enhance Moderna's capabilities in addressing niche markets, thereby diversifying its product offerings and reinforcing its competitive edge. The strategic importance of this partnership lies in its potential to accelerate the development of innovative therapies, which could significantly impact patient outcomes.
In September Alnylam Pharmaceuticals (US) received FDA approval for its latest RNAi therapeutic aimed at treating a rare genetic disorder. This approval not only validates Alnylam's innovative approach but also strengthens its market position as a leader in RNAi technology. The significance of this event is underscored by the potential for expanded applications of RNAi therapeutics, which may open new avenues for treatment in various disease areas.
In August Ionis Pharmaceuticals (US) entered into a collaboration with a major pharmaceutical company to co-develop a novel antisense drug for a prevalent neurological disorder. This strategic move is indicative of Ionis's commitment to expanding its therapeutic reach and enhancing its pipeline. The collaboration is likely to leverage both companies' strengths, potentially leading to breakthroughs in treatment options for patients with limited alternatives.
As of November the competitive trends in the RNA-based therapeutics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory landscapes and accelerating innovation. Looking ahead, competitive differentiation is expected to evolve, with a pronounced shift from price-based competition towards a focus on technological innovation, supply chain reliability, and the ability to deliver tailored therapeutic solutions.

## Recent News & Developments

The US RNA-Based Therapeutics Market has seen significant developments recently. Companies like Moderna and BioNTech continue to expand their mRNA technology beyond vaccines, focusing on treatments for a range of diseases, including cancer and rare genetic disorders. In November 2023, Alnylam Pharmaceuticals announced promising results from a Phase III trial for its RNA interference therapy, which has fueled investor interest and boosted its market valuation significantly.

In terms of mergers and acquisitions, in September 2023, Sanofi completed the acquisition of Translate Bio, enhancing its capabilities in mRNA technology for therapeutic applications. Additionally, in October 2023, Pfizer announced a partnership with BioNTech to develop combined RNA-based therapies that target infectious diseases, reflecting a growing trend towards collaboration in this sector. Government initiatives are also supporting the RNA therapeutics field, with recent funding allocated for Research and Development in genetic medicine.

Over the past few years, the US market's momentum has accelerated, fueled by an increased focus on personalized medicine and innovations in delivery systems for RNA-based drugs. With ongoing advancements and strategic collaborations, the outlook for the US RNA-Based Therapeutics Market remains robust.

## Report Scope

| MARKET SIZE 2024 | 2764.28(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2921.84(USD Million) |
| MARKET SIZE 2035 | 5085.43(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.7% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US), Silence Therapeutics (GB), Sarepta Therapeutics (US) |
| Segments Covered | Technology, Application, End Use, Delivery Method |
| Key Market Opportunities | Advancements in RNA delivery systems enhance therapeutic efficacy and expand treatment options in the rna based-therapeutics market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the RNA-based therapeutics market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US RNA based-therapeutics market?**
A: The market valuation was $2764.28 Million in 2024.

**Q: What is the projected market valuation for the US RNA based-therapeutics market by 2035?**
A: The projected valuation for 2035 is $5085.43 Million.

**Q: What is the expected CAGR for the US RNA based-therapeutics market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 5.7%.

**Q: Which technology segments are included in the US RNA based-therapeutics market?**
A: Key technology segments include RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology.

**Q: What are the valuation ranges for the mRNA Therapeutics segment in the US RNA based-therapeutics market?**
A: The mRNA Therapeutics segment is valued between $1000.0 Million and $2000.0 Million.

**Q: Which applications are driving growth in the US RNA based-therapeutics market?**
A: The primary applications include Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases.

**Q: What is the valuation range for the Oncology application in the US RNA based-therapeutics market?**
A: The Oncology application is valued between $800.0 Million and $1500.0 Million.

**Q: Who are the key players in the US RNA based-therapeutics market?**
A: Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and others.

**Q: What delivery methods are utilized in the US RNA based-therapeutics market?**
A: Delivery methods include Liposomes, Nanoparticles, Viral Vectors, and Electroporation.

**Q: What is the valuation range for Viral Vectors in the US RNA based-therapeutics market?**
A: The Viral Vectors segment is valued between $1200.0 Million and $2400.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-rna-based-therapeutics-market-52771*